{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000083","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.933478+00:00","generated_at":"2026-05-29T20:44:24.433166+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Elicio Therapeutics shareholders elect directors, ratify auditor, approve share issuance","bullets":["Three Class I directors elected: Robert Connelly (6,248,397 for), Katie Chudnovsky (6,233,264), Allen Nissenson (6,249,739).","Ratification of Baker Tilly US, LLP as auditor for FY2024: 7,434,248 for, 1,188 against, 17,558 abstain.","Approved issuance of shares upon exercise of warrants and convertible note per Nasdaq Rule 5635(b): 6,269,593 for, 81,508 against.","Quorum of 7,452,994 shares voted (69.17% of voting power); all proposals passed."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000083","json":"https://secwatch.observer/filing/0001601485-24-000083.json","markdown":"https://secwatch.observer/filing/0001601485-24-000083.md","text":"https://secwatch.observer/filing/0001601485-24-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000083/0001601485-24-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000083/angn-20241121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:44:24.433166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}